SCHEMBL6808366

SCHEMBL6808366

O=C(CCF)c1ccc(OCc2ccccc2)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.53
NPC1 O15118 2/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MRGPRX4 Q96LA9 5/20 0.51
PTGER1 P34995 1/20 0.50
S1PR5 Q9H228 1/20 0.49
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
SMPD1 P17405 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
THRA P10827 1/20 0.44
THRB P10828 1/20 0.44
ABCB1 P08183 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9341900 0.89 NPC1 (0.54) EGFRNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL5457607 0.85 MRGPRX4 (0.54) EGFRNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL4161097 0.85 NPC1 (0.53) EGFRNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL229472 0.84 MRGPRX4 (0.69) HPGDRAB9AMRGPRX4PTGER1S1PR5
SCHEMBL31031135 0.82 MRGPRX4 (0.56) NPC1HPGDRAB9ASMN1; SMN2MRGPRX4
SCHEMBL4747320 0.82 MAOB (0.59) NPC1HPGDRAB9ASMN1; SMN2MRGPRX4
SCHEMBL2744895 0.82 PARP10 (0.59) NPC1HPGDRAB9ASMN1; SMN2MRGPRX4
SCHEMBL12692658 0.82 HPGD (0.56) EGFRNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL8512033 0.81 SLC6A2 (0.57) NPC1HPGDRAB9ASMN1; SMN2MRGPRX4
SCHEMBL8512056 0.78 BRD4 (0.64) NPC1HPGDSMN1; SMN2MRGPRX4PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0828513-B1 COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS PFIZER (US) 2004-01-21 EP disclosed
EP-0777652-B1 NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES PFIZER (US) 2003-06-25 EP disclosed
US-6258827-B1 HYDROXYAROMATIC HETEROCYCLIC ALKANOLS AND LEVODOPA PFIZER INC. 2001-07-10 US disclosed
US-6046213-A Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives PFIZER INC. (US) 2000-04-04 US disclosed
EP-0828513-A2 COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS PFIZER INC. (US) 1998-03-18 EP disclosed
EP-0777652-A1 NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES PFIZER INC. (US) 1997-06-11 EP disclosed
WO-1996037226-A2 COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS PFIZER INC. (US) 1996-11-28 WO disclosed
WO-1996006081-A1 NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES PFIZER INC. (US) 1996-02-29 WO disclosed